On February 8, Prof. WU Gang and Associate Prof. XU Shuangbing from the Oncology Center of Affiliated Union Hospital published original paper online in Cell Death and Differentiation enrolled by Nature (2019 Impact Factor 10.717, real-time impact factor 13.68). The paper was titled "USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription", which was the third time the team published their researchings on radiobiology of lung cancer.

The study demonstrated that USP9X-mediated KDM4C deubiquitination activates TGF-β2/Smad signaling to promote radioresistance, suggesting that targeting KDM4C may be a promising radiosensitization strategy in the treatment of lung cancer.

Besides, the team published a research paper "UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance" in "Cell Death and Differentiation" on September 8, 2020, which reveals that UBE2O facilitates tumorigenesis and radioresistance by promoting Mxi1 ubiquitination and degradation, suggesting that UBE2O is an attractive radiosensitization target for the treatment of lung cancer.

The teams of Wu Gang and Xu Shuangbing have been engaged in lung cancer radiobiology and proteomics for a long time, and have achieved a series of original research results in the field of lung cancer radiotherapy and radioimmunity. In recent years, they have been in Cell Death & Differentiation (3 articles, 2018, 2020, 2021), J Hematol Oncol (2020), Oncogene (2 articles, 2017, 2021), Theranostics (3 articles, 2018a, 2018b, 2020), Int J Radiat Oncol Biol Phys (Top 1 magazine in the field of radiotherapy, 2 articles, 2020a, 2020b), Cancer Letters (2, 2018, 2020), etc. published multiple corresponding author papers with impact factors above 5 points and 4 papers above 10 points. The Cancer Center of Union Hospital is the only first author and corresponding author unit.